PARK2 ELISA Kit (Human) (OKCD00600)

Catalog No: OKCD00600 (Formerly GWB-KBBPZ4)

Size:96WELLS

Human PARK2 ELISA Kit standard curve

Product Info

• Predicted Species Reactivity: Homo sapiens|Human
• Application: Enzyme-linked Immunosorbent assay-Sandwich
• ELISA Kit Detection Method: Colorimetric
• ELISA Kit Duration: 3h
• ELISA Kit Principle: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Parkinson Disease Protein 2 (PARK2). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Parkinson Disease Protein 2 (PARK2). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Parkinson Disease Protein 2 (PARK2), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm +/- 10nm. The concentration of Parkinson Disease Protein 2 (PARK2) in the samples is then determined by comparing the O.D. of the samples to the standard curve.
• ELISA Kit Range: 0.156-10ng/mL
• ELISA Kit Reproducibility: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Parkinson Disease Protein 2 (PARK2) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Parkinson Disease Protein 2 (PARK2) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 Intra-Assay: CV<10% Inter-Assay: CV<12%
• ELISA Kit Component:
  • Anti-PARK2 Microplate: 96 Wells (12 x 8 Well Strips)
  • PARK2 Lyophilized Standard: 2 x 10 ng
  • 100X Biotinylated PARK2 Detector Antibody: 120 uL
  • Avidin/HRP Conjugate: 120 uL
  • Standard Diluent: 1 x 20 mL
  • Detector Antibody Diluent: 1 x 12 mL
  • Conjugate Diluent: 1 x 12 mL
  • 30X Wash Buffer: 1 x 20 mL
  • TMB Substrate: 1 x 9 mL
  • Stop Solution: 1 x 6 mL
• Reconstitution and Storage: 2°C to 8°C|-20°C
• Sample Type: Tissue homogenates and other biological fluids.
• Sensitivity: < 0.053 ng/mL
• Specificity: This assay has high sensitivity and excellent specificity for detection of Parkinson Disease Protein 2 (PARK2). No significant cross-reactivity or interference between Parkinson Disease Protein 2 (PARK2) and analogues was observed.
• Assay Info: Assay Methodology: Quantitative Sandwich Immunoassay

Target Info

• Gene Symbol: PRKN
• Gene Full Name: parkin RBR E3 ubiquitin protein ligase
• Alias Symbols: AR-JP;E3 ubiquitin-protein ligase parkin;LPRS2;PARK2;Parkin RBR E3 ubiquitin-protein ligase;Parkinson disease (autosomal recessive, juvenile) 2, parkin;parkinson juvenile disease protein 2;parkinson protein 2 E3 ubiquitin protein ligase;parkinson protein 2, E3 ubiquitin protein ligase (parkin);PDJ.
• NCBI Gene Id: 5071
• Protein Name: E3 ubiquitin-protein ligase parkin
• Description of Target: Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins, such as BCL2, SYT11, CCNE1, GPR37, RHOT1/MIRO1, MFN1, MFN2, STUB1, SNCAIP, SEPT5, TOMM20, USP30, ZNF746 and AIMP2 (PubMed:10973942, PubMed:10888878, PubMed:11431533, PubMed:12150907, PubMed:12628165, PubMed:16135753, PubMed:21376232, PubMed:23754282, PubMed:23620051, PubMed:24660806, PubMed:24751536). Mediates monoubiquitination as well as 'Lys-6', 'Lys-11', 'Lys-48'-linked and 'Lys-63'-linked polyubiquitination of substrates depending on the context (PubMed:19229105, PubMed:20889974, PubMed:25621951). Participates in the removal and/or detoxification of abnormally folded or damaged protein by mediating 'Lys-63'-linked polyubiquitination of misfolded proteins such as PARK7: 'Lys-63'-linked polyubiquitinated misfolded proteins are then recognized by HDAC6, leading to their recruitment to aggresomes, followed by degradation (PubMed:17846173, PubMed:19229105). Mediates 'Lys-63'-linked polyubiquitination of a 22 kDa O-linked glycosylated isoform of SNCAIP, possibly playing a role in Lewy-body formation (PubMed:11590439, PubMed:11431533, PubMed:19229105, PubMed:11590439, PubMed:15728840). Mediates monoubiquitination of BCL2, thereby acting as a positive regulator of autophagy (PubMed:20889974). Promotes the autophagic degradation of dysfunctional depolarized mitochondria (mitophagy) by promoting the ubiquitination of mitochondrial proteins such as TOMM20, RHOT1/MIRO1 and USP30 (PubMed:19029340, PubMed:19966284, PubMed:23620051, PubMed:24896179, PubMed:25527291). Preferentially assembles 'Lys-6'-, 'Lys-11'- and 'Lys-63'-linked polyubiquitin chains following mitochondrial damage, leading to mitophagy (PubMed:25621951). Mediates 'Lys-48'-linked polyubiquitination of ZNF746, followed by degradation of ZNF746 by the proteasome; possibly playing a role in the regulation of neuron death (PubMed:21376232). Limits the production of reactive oxygen species (ROS). Regulates cyclin-E during neuronal apoptosis. In collaboration with CHPF isoform 2, may enhance cell viability and protect cells from oxidative stress (PubMed:22082830). Independently of its ubiquitin ligase activity, protects from apoptosis by the transcriptional repression of p53/TP53 (PubMed:19801972). May protect neurons against alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation, and kainate-induced excitotoxicity (PubMed:11439185). May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. May represent a tumor suppressor gene.
• Uniprot ID: O60260
• Protein Accession #: NP_004553
• Nucleotide Accession #: NM_004562.2
• Protein Size (# AA): 465